Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...

Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...

Biogen's research organization recently went through an overhaul that company leaders say should allow the Cambridge drugmaker to increase the number of molecules that get into the clinic, and then, ...

Biogen has turned to M&A to offset its recent ... therapy dapirolizumab pegol as well as Sage Therapeutics-partnered antidepressant zuranolone, although a lack of commentary on the latter in ...

Biogen briefly moved its headquarters out to Weston, a town 30 minutes from Kendall Square, in 2010 before quickly announcing it would move back to Cambridge a year later.

Xero vs Sage: Best Accounting Software for 2025? Your email has been sent Here’s my comparison of Xero vs Sage and determine which software suits your business’ accounting and financial ...

Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2024 ,inter alia, to consider and approve Pursuant to Regulation 29 of ...

Sage Therapeutics and Biogen's antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a falloff in efficacy over time has raised concerns about the commercial potential ...

The drug, a once-daily pill called Vykat XR, was developed by Soleno Therapeutics. “The approval of Vykat XR is a significant milestone for Soleno and, most importantly, for the PWS community ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.